MGTX Stock Overview
A clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
MeiraGTx Holdings plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.48 |
| 52 Week High | US$8.75 |
| 52 Week Low | US$3.85 |
| Beta | 1.22 |
| 1 Month Change | -29.65% |
| 3 Month Change | -5.03% |
| 1 Year Change | 0.18% |
| 3 Year Change | -56.30% |
| 5 Year Change | -59.68% |
| Change since IPO | -63.47% |
Recent News & Updates
Is MeiraGTx Holdings (NASDAQ:MGTX) Using Debt Sensibly?
Apr 04
MeiraGTx Holdings: Gaining Regulatory Focus
Mar 25MeiraGTx Holdings plc's (NASDAQ:MGTX) 29% Price Boost Is Out Of Tune With Revenues
Mar 14Recent updates
Is MeiraGTx Holdings (NASDAQ:MGTX) Using Debt Sensibly?
Apr 04MeiraGTx Holdings: Gaining Regulatory Focus
Mar 25MeiraGTx Holdings plc's (NASDAQ:MGTX) 29% Price Boost Is Out Of Tune With Revenues
Mar 14MeiraGTx: 2 Possible Near-Term BLA Filings Could Ignite Shareholder Value
Jan 22Analysts Have Lowered Expectations For MeiraGTx Holdings plc (NASDAQ:MGTX) After Its Latest Results
Nov 15MeiraGTx: Positive PD Data Moves Needle Forward For Regulatory Meetings
Oct 15MeiraGTx: A Very Attractive Longer-Term Play, With Potential Near-Term Catalysts
Jul 15MeiraGTx Holdings (NASDAQ:MGTX) Has Debt But No Earnings; Should You Worry?
Jun 19MeiraGTx: Bota-Vec Program Advancing With Milestones Being Met
Feb 15Does MeiraGTx Holdings (NASDAQ:MGTX) Have A Healthy Balance Sheet?
Sep 08Calculating The Intrinsic Value Of MeiraGTx Holdings plc (NASDAQ:MGTX)
Apr 11MeiraGTx Holdings plc (NASDAQ:MGTX) Analysts Are Reducing Their Forecasts For This Year
Mar 16MeiraGTx Holdings plc (NASDAQ:MGTX) Analysts Are More Bearish Than They Used To Be
Nov 16MeiraGTx GAAP EPS of -$0.76, revenue of $10.76M
Aug 11MeiraGTx inks $100M debt agreement backed by manufacturing facilities
Aug 03Shareholder Returns
| MGTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.7% | 1.3% | 5.8% |
| 1Y | 0.2% | -11.3% | 4.8% |
Return vs Industry: MGTX exceeded the US Biotechs industry which returned -11.3% over the past year.
Return vs Market: MGTX underperformed the US Market which returned 4.8% over the past year.
Price Volatility
| MGTX volatility | |
|---|---|
| MGTX Average Weekly Movement | 12.2% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: MGTX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MGTX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 378 | Alexandria Forbes | meiragtx.com |
MeiraGTx Holdings plc, a clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also developing AAV-AQP1 in Phase 2 trial for radiation-induced grade 2/3 radiation-induced xerostomia, as well as in Phase ½ trial for Sjogren’s syndrome; AAV-GAD in Phase 2 trial for Parkinson’s disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase 2 trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4.
MeiraGTx Holdings plc Fundamentals Summary
| MGTX fundamental statistics | |
|---|---|
| Market cap | US$410.05m |
| Earnings (TTM) | -US$147.79m |
| Revenue (TTM) | US$33.28m |
13.0x
P/S Ratio-2.9x
P/E RatioIs MGTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MGTX income statement (TTM) | |
|---|---|
| Revenue | US$33.28m |
| Cost of Revenue | US$23.79m |
| Gross Profit | US$9.49m |
| Other Expenses | US$157.28m |
| Earnings | -US$147.79m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.87 |
| Gross Margin | 28.51% |
| Net Profit Margin | -444.10% |
| Debt/Equity Ratio | 108.0% |
How did MGTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/14 23:36 |
| End of Day Share Price | 2025/04/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MeiraGTx Holdings plc is covered by 14 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Huidong Wang | Barclays |
| Alec Stranahan | BofA Global Research |
| Gbolahan Amusa Benz | Chardan Capital Markets, LLC |